Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Post by theo12on Oct 09, 2018 6:24am

174 Views

Post# 28764847

RBC

SP of TH is $9.35 and went down after last results. RBC just raised its forecast to $12 on Oct 5. Because of the history of the SP since his valuation of $11, being sure that the analyst is aware of all the talks on this board, in spite of the last TH results, and because all we have from TH is news, and no solid evidence for the future, I think he has information unknown to this board and others, and might be right.

Bullboard Posts

Changing Europe’s dependency on HREE from China